Home » Saihari Sadanandan Case Series

Dr. Saihari Sadanandan Case Series on Aggrastat 

We’ve partnered with Dr. Saihari Sadanadan to offer you 3 typical cases in which he used AGGRASTAT  (tirofiban hydrochloride) injection in his practice.

The purpose of these videos is to demonstrate a typical use of AGGRASTAT for fellows and those who may not be familiar with the contemporary use of glycoprotein IIb/IIIa inhibitors (GPIs). 

About Dr. Saihari Sadanandan

Dr. Saihari Sadanandan is the Director of Tampa Cardiovascular Interventions and Research and an interventional cardiologist at three different hospitals in Tampa; St. Joseph’s Main Hospital, St. Joseph’s Hospital North, and Advent Health Carrollwood Hospital. Here he presents three cases on the typical and contemporary use of AGGRASTAT in his practice.

In this 3 part series Dr. Sadanandan presents the following cases:

  • ACS with no DAPT pre-procedure
  • Intraprocedural thrombus formation
  • Short infusion administration in a NSTE-ACS patient

ACS with no DAPT Pre-Procedure

A patient presents to the Emergency Department with Acute Coronary Syndrome (ACS) and has not received dual-antiplatelet therapy (DAPT) prior to a PCI procedure.

Intraprocedural Thrombus Formation

A case where intravenous AGGRASTAT is used in a patient who had an intraprocedural thrombus in their coronary arteries. 

Short Infusion Administration in Patient with NSTE-ACS

A patient presents to the Emergency Department with NSTE-ACE and is treated with short infusion AGGRASTAT. 

About Aggrastat

AGGRASTAT (tirofiban hydrochloride) is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). 

AGGRASTAT:

  • Offers protection during the delayed onset of the oral P2Y12 agents
  • Has a rapid onset, achieving >90% platelet aggregation inhibition within 10 minutes
  • Is reversible: platelets return to baseline function within 4 to 8 hours of discontinuation of infusion
  • Has no contraindication for patients on hemodialysis
  • Has no drug interactions with oral P2Y12 inhibitors
* Concomitant use of fibrinolytic, anticoagulants and antiplatelet drugs increases the risk of bleeding
Aggrastat Pharmacy Product

See Cases from Other Interventional Cardiologists 

We’ve partnered with physicians from across the country to offer these resources to you. Check out content from other notable healthcare providers in the U.S. that rely on AGGRASTAT to protect their patients from thrombotic complications during PCI.

Click to see the full list of available cases

Important Safety Information

Indication:

Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Contraindications:

  • Known hypersensitivity to any component of Aggrastat®.
  • History of thrombocytopenia with prior exposure to Aggrastat®.
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

  • Aggrastat® can cause serious bleeding. Most bleeding associated with Aggrastat® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue Aggrastat®.
  • Thrombocytopenia: discontinue Aggrastat® and heparin.

Adverse Reactions:

  • Bleeding is the most commonly reported adverse reaction.

For additional information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.